electroCore, Inc.

Equities

ECOR

US28531P2020

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-10 EDT			5-day change	1st Jan Change
6.84 ^USD	-0.15%		+8.14%	+14.92%

05-08	Transcript : ElectroCore, Inc., Q1 2024 Earnings Call, May 08, 2024
05-08	Earnings Flash (ECOR) ELECTROCORE Posts Q1 Revenue $5.4M, vs. Street Est of $4.8M	MT

ElectroCore, Inc. Reiterates Revenue Guidance for the Year Ending December 31, 2023

May 03, 2023 at 04:01 pm

electroCore, Inc. reiterated revenue guidance for the year ending December 31, 2023. The Company reiterated its revenue guidance of $14.0 million to $15.0 million for the year ending December 31, 2023.

Latest news about electroCore, Inc.

Transcript : ElectroCore, Inc., Q1 2024 Earnings Call, May 08, 2024	05-08
Earnings Flash (ECOR) ELECTROCORE Posts Q1 Revenue $5.4M, vs. Street Est of $4.8M	05-08	MT
ElectroCore, Inc. Appoints Donald Melnikoff as SVP, Engineering, Regulatory, and Compliance	05-03	CI
ElectroCore, Inc. Announces Results of Truvaga Plus Consumer Study	04-30	CI
ElectroCore, Inc. Announces the Launch of Truvaga Plus® for General Wellness	04-08	CI
ElectroCore, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-13	CI
Transcript : ElectroCore, Inc., Q4 2023 Earnings Call, Mar 13, 2024	03-13
ElectroCore, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-13	CI
Earnings Flash (ECOR) ELECTROCORE Posts Q4 Revenue $5.2M, vs. Street Est of $5M	03-13	MT
Certain Common Stock of electroCore, Inc. are subject to a Lock-Up Agreement Ending on 28-JAN-2024.	01-27	CI
Certain Warrants of electroCore, Inc. are subject to a Lock-Up Agreement Ending on 28-JAN-2024.	01-27	CI
Certain Options of electroCore, Inc. are subject to a Lock-Up Agreement Ending on 28-JAN-2024.	01-27	CI
HC Wainwright Adjusts electroCore Price Target to $15 From $11, Maintains Buy Rating	01-22	MT
Ondine Biomedical appoints Joseph Errico as new CFO	01-16	AN
ElectroCore Says Two US Patents Issued for Non-Invasive Vagus Nerve Stimulation Technology	12-26	MT
ElectroCore, Inc. Appoints Charles S. Theofilos as New Class Iii Member of the Board	12-14	CI
Transcript : ElectroCore, Inc. - Analyst/Investor Day	11-21
HC Wainwright Adjusts Price Target on electroCore to $11 From $10, Maintains Buy Rating	11-09	MT
Transcript : ElectroCore, Inc., Q3 2023 Earnings Call, Nov 08, 2023	11-08
ElectroCore, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
Earnings Flash (ECOR) ELECTROCORE Posts Q3 Revenue $4.5M, vs. Street Est of $3.8M	11-08	MT
Electrocore, Inc. Announces Data Highlighting Non-Invasive Vagus Nerve Stimulation for Treatment of Symptoms of Gastroparesis	23-10-24	CI
ElectroCore, Inc. Announces Two-Year Extension of Gammacore Device Listing in the NHS Supply Chain Catalogue	23-10-17	CI
ElectroCore, Inc. Announces the Publication of Two Peer Reviewed Publication of Two Peer Reviewed Publications Supporting the Use of Gammacore ( Non-Invasive Vagus Nerve Stimulation; nVNS) in Patients with Post Traumatic Stress Disorder	23-09-27	CI
ElectroCore Wins Dismissal of Lawsuit Over 2018 Initial Public Offering	23-08-23	MT

Chart electroCore, Inc.

Duration

Period

More charts

Company Profile

electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company. It provides non-invasive vagus nerve stimulation (nVNS) technology platform. The Companyâs product categories include Handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headache, and Handheld, personal use consumer products utilizing nVNS technology to promote general wellness and human performance. Its products include gammaCore, Truvaga and TAC-STIM. Its gammaCore Sapphire, is a prescription medical device that is used for a variety of primary headache conditions. Its Truvaga is a personal use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com. The Companyâs TAC-STIM product is not a medical device and is not intended to diagnose, cure, mitigate, prevent, or treat a disease or condition.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-13 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for electroCore, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.84 USD

Average target price

23.16 USD

Spread / Average Target

+238.65%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Equipment

	1st Jan change	Capi.
ELECTROCORE, INC.	+14.92%	41.06M
SHOCKWAVE MEDICAL, INC.	+73.46%	12.41B
PENUMBRA, INC.	-15.61%	8.23B
MASIMO CORPORATION	+3.88%	6.46B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+14.69%	5.5B
GETINGE AB	-5.53%	5.33B
APT MEDICAL INC.	+42.58%	5.1B
INARI MEDICAL, INC.	-32.61%	2.54B
SHENZHEN YHLO BIOTECH CO., LTD.	+10.80%	1.99B
SKAN GROUP AG	-0.74%	1.99B

Medical Equipment